These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 8548755)
1. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755 [TBL] [Abstract][Full Text] [Related]
3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005 [TBL] [Abstract][Full Text] [Related]
4. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Geradts J; Kratzke RA; Niehans GA; Lincoln CE Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382 [TBL] [Abstract][Full Text] [Related]
6. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773 [TBL] [Abstract][Full Text] [Related]
7. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Schmidt EE; Ichimura K; Reifenberger G; Collins VP Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821 [TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Brenner AJ; Aldaz CM Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417 [TBL] [Abstract][Full Text] [Related]
9. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines. Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982 [TBL] [Abstract][Full Text] [Related]
10. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516 [TBL] [Abstract][Full Text] [Related]
11. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437 [TBL] [Abstract][Full Text] [Related]
12. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819 [TBL] [Abstract][Full Text] [Related]
14. Increased p16 levels correlate with pRb alterations in human urothelial cells. Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615 [TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. Heidenreich A; Gaddipati JP; Moul JW; Srivastava S J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401 [TBL] [Abstract][Full Text] [Related]
18. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Jarrard DF; Sarkar S; Shi Y; Yeager TR; Magrane G; Kinoshita H; Nassif N; Meisner L; Newton MA; Waldman FM; Reznikoff CA Cancer Res; 1999 Jun; 59(12):2957-64. PubMed ID: 10383161 [TBL] [Abstract][Full Text] [Related]
19. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335 [TBL] [Abstract][Full Text] [Related]
20. Loss of P16INK4 expression is frequent in high grade gliomas. Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]